Kyverna Therapeutics, Inc. (KYTX) vs Neurogene Inc. (NGNE)
A side-by-side comparison of Kyverna Therapeutics, Inc. and Neurogene Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KYTX
Kyverna Therapeutics, Inc.
$6.36HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
NGNE
Neurogene Inc.
$25.94HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — KYTX vs NGNE
growth of $100 · dividends reinvested · last 3yKYTX -78.9% (-40.5%/yr)NGNE -17.3% (-6.1%/yr)NGNE compounded faster over this window
KYTX NGNE
KYTX vs NGNE: by the numbers
- •NGNE is the larger company ($410M vs $387M market cap).
Metrics side by side
Valuation
| Metric | KYTX | NGNE |
|---|---|---|
| P/B ratio | 2.34 | 1.89 |
Profitability
| Metric | KYTX | NGNE |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -92.20% | -51.17% |
| ROIC | -80.67% | -54.45% |
Growth (annualized)
| Metric | KYTX | NGNE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -27.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.